Clear all

Refine your search

Content type

2,821 results found

Arnold & Porter logo
Arnold & Porter is a firm of nearly 1,000 lawyers, providing sophisticated litigation and transactional capabilities, renowned regulatory experience…
Ask Lexy

Arnold & Porter | USA | 3 Apr 2023

Risk & Compliance Management in USA

Press release

Arnold & Porter | USA | 27 Mar 2023

New York Fed Veteran James Bergin Joins Arnold & Porter

Arnold & Porter announced today that James P. Bergin, who has held senior legal positions at the Federal Reserve Bank of New York, including as its…
Press release

Arnold & Porter | USA | 6 Mar 2023

Arnold & Porter’s Corporate & Finance Practice Grows with Partner Marina Richter

Arnold & Porter announced today the continued growth of its Corporate & Finance practice with the arrival of partner Marina Richter. She will be…
Press release

Arnold & Porter | USA | 6 Feb 2023

Former US Representative Ron Kind Joins Arnold & Porter’s Legislative & Public Policy Practice as Senior Policy Advisor

Arnold & Porter is pleased to announce that former United States Representative Ron Kind (D-WI) has joined the firm's Legislative & Public Policy…
Ask Lexy

Arnold & Porter | United Kingdom | 21 Nov 2022

Intellectual Property & Antitrust in United Kingdom


Intellectual Property & Antitrust

Editor: Matthew Tabas

Arnold & Porter

Quick reference guide enabling side-by-side comparison of local insights, including into intellectual property law, the nexus between competition and IP rights, and consideration of industry standards; competition law, including such issues as interactions with copyright exhaustion or first sale doctrines; merger review; specific examples of competition law violations; remedies; economics and application of competition law; recent cases, remedies and sanctions; and other recent trends.

Ask Lexy

Arnold & Porter | Global | 17 Nov 2022

Intellectual Property & Antitrust: Global overview

In-depth PRO
Ask Lexy

Arnold & Porter Kaye Scholer LLP | European Union | 21 Oct 2022

Cooperative Agreements: a Private Practitioner’s Perspective

The covid-19 pandemic has been an opportunity for actors across the pharmaceutical supply chain to demonstrate the benefits that swift and flexible cooperation can bring to the industry.
Previous page 1 2 3 ...